Search research articles
Contact Us
Filters
Showing results (11-20 of 643) with videos related to
Page
of 65
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
February 20, 2026
Highlights in chronic lymphocytic leukemia from the 67th ASH Annual Meeting and Exposition: commentary
Susan O'Brien
Journal of Oncology Practice
|
February 15, 2019
Poor Penetration of Existing Effective Chemoimmunotherapy for the Treatment of Older Patients With Newly Diagnosed Acute Lymphocytic Leukemia (ALL) or Refractory/Relapsed ALL
Hagop Kantarjian, Susan O'Brien
Blood
|
June 13, 2015
Initial treatment of CLL: integrating biology and functional status
Nitin Jain, Susan O'Brien
Hematology. American Society of Hematology. Education Program
|
December 4, 2016
Novel agents in chronic lymphocytic leukemia
Nicole Lamanna, Susan O'Brien
Best Practice & Research. Clinical Haematology
|
October 16, 2016
B cell receptor inhibition as a target for CLL therapy
Deepa Jeyakumar, Susan O'Brien
Blood Reviews
|
June 21, 2005
Infections associated with purine analogs and monoclonal antibodies
Farhad Ravandi, Susan O'Brien
Expert Review of Anticancer Therapy
|
March 11, 2005
Alemtuzumab
Farhad Ravandi, Susan O'Brien
Cancer Investigation
|
November 23, 2006
Alemtuzumab in CLL and other lymphoid neoplasms
Farhad Ravandi, Susan O'brien
Oncology (Williston Park, N.Y.)
|
January 22, 2013
Chronic lymphocytic leukemia with deletion 17p: emerging treatment options
Nitin Jain, Susan O'Brien
Expert Opinion on Biological Therapy
|
December 22, 2012
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
Preetesh Jain, Susan O'Brien
Page
of 65
Search research articles
Search
Showing results (11-20 of 643) with videos related to
Sort By:
Page
of 65
Clinical Advances in Hematology & Oncology : H&O
|
February 20, 2026
Highlights in chronic lymphocytic leukemia from the 67th ASH Annual Meeting and Exposition: commentary
Susan O'Brien
Journal of Oncology Practice
|
February 15, 2019
Poor Penetration of Existing Effective Chemoimmunotherapy for the Treatment of Older Patients With Newly Diagnosed Acute Lymphocytic Leukemia (ALL) or Refractory/Relapsed ALL
Hagop Kantarjian, Susan O'Brien
Blood
|
June 13, 2015
Initial treatment of CLL: integrating biology and functional status
Nitin Jain, Susan O'Brien
Hematology. American Society of Hematology. Education Program
|
December 4, 2016
Novel agents in chronic lymphocytic leukemia
Nicole Lamanna, Susan O'Brien
Best Practice & Research. Clinical Haematology
|
October 16, 2016
B cell receptor inhibition as a target for CLL therapy
Deepa Jeyakumar, Susan O'Brien
Blood Reviews
|
June 21, 2005
Infections associated with purine analogs and monoclonal antibodies
Farhad Ravandi, Susan O'Brien
Expert Review of Anticancer Therapy
|
March 11, 2005
Alemtuzumab
Farhad Ravandi, Susan O'Brien
Cancer Investigation
|
November 23, 2006
Alemtuzumab in CLL and other lymphoid neoplasms
Farhad Ravandi, Susan O'brien
Oncology (Williston Park, N.Y.)
|
January 22, 2013
Chronic lymphocytic leukemia with deletion 17p: emerging treatment options
Nitin Jain, Susan O'Brien
Expert Opinion on Biological Therapy
|
December 22, 2012
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
Preetesh Jain, Susan O'Brien
Page
of 65